vs
ALTA EQUIPMENT GROUP INC.（ALTG）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是ALTA EQUIPMENT GROUP INC.的1.5倍（$772.1M vs $509.1M），Revvity净利率更高（12.7% vs -2.3%，领先15.0%），Revvity同比增速更快（5.9% vs 2.2%），Revvity自由现金流更多（$161.8M vs $32.8M），过去两年Revvity的营收复合增速更高（9.0% vs 7.4%）
阿尔塔汽车工程公司是英国的运动及赛车制造商，常简称为Alta。在1950年至1952年间，该公司的赛车参加了五场国际汽联世界锦标赛，在此之前也参与过多场大奖赛赛事，同时还为少数其他制造商提供引擎，最知名的客户是康诺特和HWM车队。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
ALTG vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.5倍
$509.1M
营收增速更快
RVTY
高出3.6%
2.2%
净利率更高
RVTY
高出15.0%
-2.3%
自由现金流更多
RVTY
多$129.0M
$32.8M
两年增速更快
RVTY
近两年复合增速
7.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $509.1M | $772.1M |
| 净利润 | $-11.7M | $98.4M |
| 毛利率 | 23.5% | — |
| 营业利润率 | 1.0% | 14.5% |
| 净利率 | -2.3% | 12.7% |
| 营收同比 | 2.2% | 5.9% |
| 净利润同比 | -10.4% | 3.9% |
| 每股收益（稀释后） | $-0.38 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALTGRVTY
| Q4 25 | $509.1M | $772.1M | ||
| Q3 25 | $422.6M | $698.9M | ||
| Q2 25 | $481.2M | $720.3M | ||
| Q1 25 | $423.0M | $664.8M | ||
| Q4 24 | $498.1M | $729.4M | ||
| Q3 24 | $448.8M | $684.0M | ||
| Q2 24 | $488.1M | $691.7M | ||
| Q1 24 | $441.6M | $649.9M |
净利润ALTGRVTY
| Q4 25 | $-11.7M | $98.4M | ||
| Q3 25 | $-41.6M | $46.7M | ||
| Q2 25 | $-6.1M | $53.9M | ||
| Q1 25 | $-20.9M | $42.2M | ||
| Q4 24 | $-10.6M | $94.6M | ||
| Q3 24 | $-27.7M | $94.4M | ||
| Q2 24 | $-11.9M | $55.4M | ||
| Q1 24 | $-11.9M | $26.0M |
毛利率ALTGRVTY
| Q4 25 | 23.5% | — | ||
| Q3 25 | 27.9% | 53.6% | ||
| Q2 25 | 25.4% | 54.5% | ||
| Q1 25 | 27.2% | 56.5% | ||
| Q4 24 | 23.4% | — | ||
| Q3 24 | 27.8% | 56.3% | ||
| Q2 24 | 27.0% | 55.7% | ||
| Q1 24 | 27.3% | 54.6% |
营业利润率ALTGRVTY
| Q4 25 | 1.0% | 14.5% | ||
| Q3 25 | 1.1% | 11.7% | ||
| Q2 25 | 2.6% | 12.6% | ||
| Q1 25 | 0.2% | 10.9% | ||
| Q4 24 | 0.5% | 16.3% | ||
| Q3 24 | 1.5% | 14.3% | ||
| Q2 24 | 2.1% | 12.4% | ||
| Q1 24 | -0.2% | 6.8% |
净利率ALTGRVTY
| Q4 25 | -2.3% | 12.7% | ||
| Q3 25 | -9.8% | 6.7% | ||
| Q2 25 | -1.3% | 7.5% | ||
| Q1 25 | -4.9% | 6.4% | ||
| Q4 24 | -2.1% | 13.0% | ||
| Q3 24 | -6.2% | 13.8% | ||
| Q2 24 | -2.4% | 8.0% | ||
| Q1 24 | -2.7% | 4.0% |
每股收益（稀释后）ALTGRVTY
| Q4 25 | $-0.38 | $0.86 | ||
| Q3 25 | $-1.31 | $0.40 | ||
| Q2 25 | $-0.21 | $0.46 | ||
| Q1 25 | $-0.65 | $0.35 | ||
| Q4 24 | $-0.34 | $0.77 | ||
| Q3 24 | $-0.86 | $0.77 | ||
| Q2 24 | $-0.38 | $0.45 | ||
| Q1 24 | $-0.38 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $18.6M | $919.9M |
| 总债务越低越好 | $724.0M | — |
| 股东权益账面价值 | $-8.8M | $7.3B |
| 总资产 | $1.3B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ALTGRVTY
| Q4 25 | $18.6M | $919.9M | ||
| Q3 25 | $14.1M | $931.4M | ||
| Q2 25 | $13.2M | $991.8M | ||
| Q1 25 | $11.1M | $1.1B | ||
| Q4 24 | $13.4M | $1.2B | ||
| Q3 24 | $14.6M | $1.2B | ||
| Q2 24 | $4.5M | $2.0B | ||
| Q1 24 | $5.6M | $1.7B |
总债务ALTGRVTY
| Q4 25 | $724.0M | — | ||
| Q3 25 | $745.6M | — | ||
| Q2 25 | $732.6M | — | ||
| Q1 25 | $735.0M | — | ||
| Q4 24 | $695.3M | — | ||
| Q3 24 | $712.6M | — | ||
| Q2 24 | $727.3M | — | ||
| Q1 24 | $674.4M | — |
股东权益ALTGRVTY
| Q4 25 | $-8.8M | $7.3B | ||
| Q3 25 | $2.9M | $7.4B | ||
| Q2 25 | $43.9M | $7.6B | ||
| Q1 25 | $56.0M | $7.6B | ||
| Q4 24 | $77.6M | $7.7B | ||
| Q3 24 | $95.7M | $7.9B | ||
| Q2 24 | $125.2M | $7.9B | ||
| Q1 24 | $136.9M | $7.8B |
总资产ALTGRVTY
| Q4 25 | $1.3B | $12.2B | ||
| Q3 25 | $1.4B | $12.1B | ||
| Q2 25 | $1.4B | $12.4B | ||
| Q1 25 | $1.5B | $12.4B | ||
| Q4 24 | $1.5B | $12.4B | ||
| Q3 24 | $1.5B | $12.8B | ||
| Q2 24 | $1.6B | $13.4B | ||
| Q1 24 | $1.6B | $13.4B |
负债/权益比ALTGRVTY
| Q4 25 | — | — | ||
| Q3 25 | 257.10× | — | ||
| Q2 25 | 16.69× | — | ||
| Q1 25 | 13.13× | — | ||
| Q4 24 | 8.96× | — | ||
| Q3 24 | 7.45× | — | ||
| Q2 24 | 5.81× | — | ||
| Q1 24 | 4.93× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $33.9M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $32.8M | $161.8M |
| 自由现金流率自由现金流/营收 | 6.4% | 21.0% |
| 资本支出强度资本支出/营收 | 0.2% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $23.8M | $509.4M |
8季度趋势，按日历期对齐
经营现金流ALTGRVTY
| Q4 25 | $33.9M | $182.0M | ||
| Q3 25 | $2.5M | $138.5M | ||
| Q2 25 | $14.1M | $134.3M | ||
| Q1 25 | $-17.5M | $128.2M | ||
| Q4 24 | $34.9M | $174.2M | ||
| Q3 24 | $46.3M | $147.9M | ||
| Q2 24 | $-10.7M | $158.6M | ||
| Q1 24 | $-13.5M | $147.6M |
自由现金流ALTGRVTY
| Q4 25 | $32.8M | $161.8M | ||
| Q3 25 | $-1.7M | $120.0M | ||
| Q2 25 | $11.9M | $115.5M | ||
| Q1 25 | $-19.2M | $112.2M | ||
| Q4 24 | $30.9M | $149.8M | ||
| Q3 24 | $42.1M | $125.6M | ||
| Q2 24 | $-13.5M | $136.6M | ||
| Q1 24 | $-17.9M | $129.7M |
自由现金流率ALTGRVTY
| Q4 25 | 6.4% | 21.0% | ||
| Q3 25 | -0.4% | 17.2% | ||
| Q2 25 | 2.5% | 16.0% | ||
| Q1 25 | -4.5% | 16.9% | ||
| Q4 24 | 6.2% | 20.5% | ||
| Q3 24 | 9.4% | 18.4% | ||
| Q2 24 | -2.8% | 19.7% | ||
| Q1 24 | -4.1% | 20.0% |
资本支出强度ALTGRVTY
| Q4 25 | 0.2% | 2.6% | ||
| Q3 25 | 1.0% | 2.6% | ||
| Q2 25 | 0.5% | 2.6% | ||
| Q1 25 | 0.4% | 2.4% | ||
| Q4 24 | 0.8% | 3.4% | ||
| Q3 24 | 0.9% | 3.3% | ||
| Q2 24 | 0.6% | 3.2% | ||
| Q1 24 | 1.0% | 2.7% |
现金转化率ALTGRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALTG
| New And Used Equipment Sales | $300.9M | 59% |
| Parts Sales | $68.1M | 13% |
| Services | $59.3M | 12% |
| Rental Equipment Sales | $38.0M | 7% |
| Design And Build Projects Automated Equipment Installation And System Integration Services | $18.5M | 4% |
| Design And Build Solutions Automated Equipment Installation And System Integration And Software Services | $14.6M | 3% |
| Master Distribution Segment | $14.0M | 3% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
